|
|
|
|
|
|
|
|
|
|
|
º¸µµÀÚ·á
|
4Â÷ »ê¾÷Çõ¸íÀÇ Áß½É, ¹ÙÀÌ¿ÀÀǾàÇ° ÀνÄÁÖ°£ ¸Â¾Æ ´Ù¾çÇÑ ±¹Á¦Çà»ç °³ÃÖ
¡à ½ÄÇ°ÀǾàÇ°¾ÈÀüó(óÀå ¼Õ¹®±â)´Â Àηù °Ç°¿¡ ÁßÃßÀû ¿ªÇÒÀ» ´ã´çÇÏ´Â ¹ÙÀÌ¿ÀÀǾàÇ°ÀÇ Á߿伺À» ¾Ë¸®°í ¹ÙÀÌ¿ÀÀǾàÇ° »ê¾÷À» ¿ì¸®³ª¶ó ¹Ì·¡ Çٽɻê¾÷À¸·Î À°¼ºÇϱâ À§ÇÑ Àü·« µîÀ» °øÀ¯Çϱâ À§ÇÏ¿© ¿À´Â 26ÀϺÎÅÍ 30ÀϱîÁö¸¦ ¡®¹ÙÀÌ¿ÀÀÎ½Ä ÁÖ°£¡¯À¸·Î ÁöÁ¤ÇÏ°í ´Ù¾çÇÑ ±¹Á¦Çà»ç¸¦ °³ÃÖÇÑ´Ù°í ¹àÇû´Ù.
¡Û À̹ø ÁÖ°£Àº 4Â÷ »ê¾÷Çõ¸íÀÇ Áß½ÉÀ¸·Î ºÎ»óÇÑ ¹ÙÀÌ¿ÀÀǾàÇ°»ê¾÷ÀÇ Á߿伺¿¡ ´ëÇØ °ø°¨´ë¸¦ Çü¼ºÇÏ°í, °ü·Ã »ê¾÷À» À°¼ºÇϱâ À§ÇÏ¿© ¿ÃÇØ Ã³À½ ÁöÁ¤µÇ¾úÀ¸¸ç, ±¹³»¡¤¿Ü ¼®ÇеéÀ» ÃÊ´ëÇÏ¿© ¹ÙÀÌ¿ÀÀǾàÇ° °³¹ß°ú °ü·ÃÇÑ ÃֽŠµ¿Çâ°ú ±ÔÁ¦ Á¤º¸ µîÀ» °øÀ¯ÇÑ´Ù.
¡à À̹ø ¡®¹ÙÀÌ¿ÀÀÎ½Ä ÁÖ°£¡¯ ÁÖ¿äÇà»ç´Â ¡ãÀǾàÇ°½Ç»ç»óÈ£Çù·Â±â±¸(PIC/S) Àü¹®°¡ºÐ°ú ȸÀÇ ¡ãWHO¿Í ±¹³» Á¦¾à»ç 1:1 ¹ÌÆà ¡ã÷´Ü¹ÙÀÌ¿ÀÀǾàÇ° Ưº°ÀÚ¹®´Ü Æ÷·³ ¡ã±Û·Î¹ú¹ÙÀÌ¿ÀÄÜÆÛ·±½ºÀÌ´Ù.
¡Û ±Û·Î¹ú¹ÙÀÌ¿ÀÄÜÆÛ·±½º(6.28-6.30)¿¡¼´Â ¡®4Â÷ »ê¾÷Çõ¸íÀÇ Áß½É, ¹ÙÀÌ¿ÀÀǾàÇ°¡¯À» ÁÖÁ¦·Î ¹ÙÀÌ¿ÀÀǾàÇ° ºÐ¾ß ¼¼°èÀû ±ÇÀ§ÀÚ, ±ÔÁ¦´ç±¹ÀÚµé°ú ÇÔ²² ¿ì¸®³ª¶ó ¹ÙÀÌ¿ÀÀǾàÇ°À» ¼¼°èÀû ºê·£µå·Î À°¼ºÇϱâ À§ÇÑ Áö½Ä°ú °æÇèÀ» °øÀ¯ÇÑ´Ù.
- ƯÈ÷ ±âÁ¶°¿¬¿¡¼´Â ±Û·Î¹úÁ¦¾à°±¹ À°¼ºÀü·«°ú ¹ÙÀÌ¿ÀÇコÄÉ¾î »õ·Î¿î Æз¯´ÙÀÓ µî¿¡ ´ëÇØ ¸¶ÀÌŬ ¿þÀÌ³Ê IBM ÇコÄÉ¾î ¼ö¼®ÀÇ·áÁ¤º¸ Ã¥ÀÓÀÚ µîÀÌ ¹ßÇ¥ÇÑ´Ù.
- ¶ÇÇÑ ¹é½Å, ¼¼Æ÷¡¤À¯ÀüÀÚÄ¡·áÁ¦, À¯ÀüÀÚÀçÁ¶ÇÕ µî ¹ÙÀÌ¿ÀÀǾàÇ° ºÐ¾ßº° Æ÷·³°ú GMP, ÀÎüÁ¶Á÷ Æ÷·³ÀÌ °³ÃֵǸç, Ưº°Çà»ç·Î ±¹³» Á¦¾à»ç°¡ ¼öÃâÀ» Èñ¸ÁÇÏ´Â Áö¿ªÀÇ ÇØ¿Ü ±ÔÁ¦ ´ç±¹ÀÚ¿ÍÀÇ 1:1 ¹ÌÆÃÀ» ÁÖ¼±ÇÑ´Ù.......´õ º¸±â
|
|
|
º¸µµÀÚ·á
|
½Ä¾àó, ¹ÙÀÌ¿À½Ã¹Ð·¯ Çã°¡½É»ç ºÐ¾ß ¿ª·® ´Ù½Ã ÇÑ ¹ø ÀÔÁõ
- ±¹Á¦ÀǾàÇ°±ÔÁ¦ÀÚÆ÷·³ ¹ÙÀÌ¿À½Ã¹Ð·¯ ¿öÅ·±×·ì ÀÇÀå±¹ ¿¬ÀÓ -
¡à ½ÄÇ°ÀǾàÇ°¾ÈÀüó(óÀå ¼Õ¹®±â)´Â ¡®2017³â »ó¹Ý±â ±¹Á¦ÀǾàÇ°±ÔÁ¦ÀÚÆ÷·³(IPRF) ¹× ±¹Á¦ÀǾàÇ°±ÔÁ¦Á¶ÈÀ§¿øȸ(ICH) ÃÑȸ¡¯¿¡¼ ¿ì¸®³ª¶ó°¡ IPRF ¹ÙÀÌ¿À½Ã¹Ð·¯ À§Å·±×·ì ÀÇÀå±¹À¸·Î ¿¬ÀӵǾú´Ù°í ¹àÇû´Ù.
¡Ø ¹ÙÀÌ¿À½Ã¹Ð·¯ ¿öÅ·±×·ì : ¹Ì±¹, À¯·´ µî 11°³±¹ ±ÔÁ¦±â°ü ¹× 3°³ ±¹Á¦´Üü ¼Ò¼Ó 32¸í ±¸¼ºµÊ
¡Ø ICH ÃÑȸ: ij³ª´Ù ¸óÆ®¸®¿Ã °³ÃÖ(5.28¡6.1)
¡Û À̹ø ¿¬ÀÓÀ¸·Î ¿ì¸®³ª¶ó´Â ¹ÙÀÌ¿À½Ã¹Ð·¯ Çã°¡¡¤½É»ç ºÐ¾ß¿¡ ´ëÇÑ ¿ª·®À» ±¹Á¦ÀûÀ¸·Î ´Ù½ÃÇѹø ÀÎÁ¤¹Þ¾ÒÀ¸¸ç, ¡¯19³â±îÁö ¹ÙÀÌ¿À½Ã¹Ð·¯ ºÐ¾ßÀÇ ±ÔÁ¦Á¶È ¼±µµ¿¡ ÁßÃßÀû ¿ªÇÒÀ» ´ã´çÇÏ°Ô µÈ´Ù.
¡Û Âü°í·Î IPRF´Â ÀǾàÇ° ±ÔÁ¦ °ü·Ã Á¤º¸±³È¯ ¹× »óÈ£Çù·ÂÀ» À§ÇØ ±¸¼ºµÈ ±ÔÁ¦´ç±¹ÀÚ°£ ȸÀÇü·Î¼ ¹ÙÀÌ¿À½Ã¹Ð·¯, ¼¼Æ÷Ä¡·áÁ¦ µî 4°³ ¿öÅ·±×·ìÀ» ¿î¿µÇÏ°í ÀÖ´Ù.
- ¿ì¸®³ª¶ó´Â ¼¼°è ÃÖÃÊ·Î Ç×ü ¹ÙÀÌ¿À½Ã¹Ð·¯¸¦ Çã°¡ÇÏ´Â µî ±ÔÁ¦±â°üÀÇ ½Å·Ú¼ºÀ» ÀÎÁ¤¹Þ¾Æ ¡®14³â ICH ºñȸ¿ø ±¹°¡·Î´Â óÀ½À¸·Î ¹ÙÀÌ¿À½Ã¹Ð·¯ ¿öÅ·±×·ì ÀÇÀå±¹À¸·Î ¼±ÃâµÇ¾ú´Ù.......... ´õ º¸±â
|
|
°³Á¤°í½Ã
|
¡¸»ý¹°ÇÐÀûÁ¦Á¦ µîÀÇ Ç°¸ñÇã°¡¡¤½É»ç ±ÔÁ¤¡¹ ÀϺΰ³Á¤°í½Ã
ÁÖ¿ä ³»¿ë
°¡. À¯ÀüÀÚ ±³Á¤ ±â¼ú µî °³¹ßµÇ°í ÀÖ´Â À¯ÀüÀÚÄ¡·áÁ¦ÀÇ Æ¯¼ºÀ» ¹Ý¿µÇÑ Á¤ÀÇ °³¼±(¾È Á¦2Á¶Á¦15È£)
³ª. ¹ÙÀÌ¿ÀÀǾàÇ° Çã°¡½É»çÀÇ ½Å¼Ó¼º°ú ¿¹Ãø¼º Á¦°í¸¦ À§ÇØ Ç°¸ñÇã°¡ ½É»ç ½Ã ±¸ºñÀÚ·á ¿ä°Ç ¹Ìºñ¿©ºÎ¿¡ ´ëÇÑ ½Å¼Ó °ËÅ並 À§ÇÑ ¿¹ºñ½É»ç Á¦µµ µµÀÔ(¾È Á¦2Á¶Á¦25È£, Á¦38Á¶Á¦1Ç× ½Å¼³)).......´õ º¸±â
¢º ¡¸»ý¹°ÇÐÀûÁ¦Á¦ µîÀÇ Ç°¸ñÇã°¡¡¤½É»ç ±ÔÁ¤¡¹ Àü¹® º¸·¯°¡±â
|
|
°³Á¤°í½Ã
|
¡¸Èñ±ÍÀǾàÇ° ÁöÁ¤¿¡ °üÇÑ ±ÔÁ¤¡¹ ÀϺΰ³Á¤°í½Ã
ÁÖ¿ä ³»¿ë
°¡. µ¿Á¾Áö¹æÀ¯·¡ Áß°£¿±Áٱ⼼Æ÷¸¦ °³¹ß´Ü°è Èñ±ÍÀǾàÇ°À¸·Î ½Å±Ô ÁöÁ¤ÇÏ°í ÀÌ¹Ì Èñ±ÍÀǾàÇ°À¸·Î ÁöÁ¤ÇÑ ¼¼¸®Æ¼´ÕÀÇ ´ë»óÁúȯÀ» º¯°æÇÔ.(¾È º°Ç¥ 1 ¹× º°Ç¥ 2)
1) Àû¿ë´ë»óÀÌ µå¹°°í ÀûÀýÇÑ ´ëüÀǾàÇ°ÀÌ ¾ø¾î ±ä±ÞÇÑ µµÀÔÀÌ ÇÊ¿äÇÑ ÀǾàÇ°À» Èñ±ÍÀǾàÇ°À¸·Î Ãß°¡ ÁöÁ¤ÇÒ ÇÊ¿ä°¡ ÀÖÀ½.
2) µ¿Á¾Áö¹æÀ¯·¡ Áß°£¿±Áٱ⼼Æ÷¸¦ °³¹ß´Ü°è Èñ±ÍÀǾàÇ°À¸·Î »õ·Ó°Ô ÁöÁ¤ÇÏ°í, ÀÌ¹Ì Èñ±ÍÀǾàÇ°À¸·Î ÁöÁ¤ÇÑ ¼¼¸®Æ¼´ÕÀÇ ´ë»óÁúȯÀ» º¯°æÇÔ.
3) Èñ±ÍÀǾàÇ° ÁöÁ¤À» È®´ëÇÔÀ¸·Î½á Èñ±ÍÁúȯ ȯÀÚÀÇ Ä¡·áÁ¦ ¼±Åà ±âȸ°¡ ´õ¿í Ä¿Áú °ÍÀ¸·Î ±â´ëµÊ. ........´õ º¸±â
|
|
ÀÇ°ßÁ¶È¸
|
ÀÇ¿ø¹ßÀÇ ¡¸±¹°¡ÇʼöÀǾàÇ°ÀÇ °ø±Þ ¹× °ü¸®¿¡ °üÇÑ ¹ý·ü¡¹Á¦Á¤(¾È) ÀÇ°ßÁ¶È¸ (±Ç¹ÌÇõ ÀÇ¿ø ´ëÇ¥¹ßÀÇ)
ÁÖ¿ä ³»¿ë
±¹°¡ÇʼöÀǾàÇ°°ü¸®Á¾ÇÕ°èȹÀÇ ¼ö¸³ µî ±¹°¡ÇʼöÀǾàÇ°°ü¸®¿¡ °üÇÑ Áß¿äÇÑ »çÇ×À» ½ÉÀÇÇϱâ À§ÇÏ¿© ±¹¹«ÃѸ® ¼Ò¼ÓÀ¸·Î ±¹°¡ÇʼöÀÇ ¾àÇ°°ü¸®À§¿øȸ¸¦ µÎ°í, ÀÌ¿Í °ü·ÃÇÑ ¿¬±¸»ç¾÷, Åë°èÁ¶»ç»ç¾÷ ¹× Á¤º¸»ç¾÷À» ½ÃÇàÇÔ. º¸°Çº¹ÁöºÎÀå°ü¼Ò¼ÓÀ¸·Î °ø°øÁ¦¾à»ç¸¦ ¼³¸³ÇÏ°í °ø°øÁ¦¾à»ç´Â ±¹°¡ÇʼöÀǾàÇ°ÀÇ °ø±Þ°ú °ü¸® µîÀÇ »ç¾÷À» ¼öÇàÇϵµ·Ï ÇÔ
ÀÇ°ß Á¦Ãâ ±âÇÑ: '17. 06. 28(¼ö)
Á¦Ãâ ¾ç½ÄÀº Çùȸ ȨÆäÀÌÁö¿¡¼ È®ÀÎÇϽñ⠹ٶø´Ï´Ù........´õ º¸±â
|
|
ä¿ë°ø°í
|
½ÄÇ°ÀǾàÇ°¾ÈÀüó (½ÄÇ°ÀǾàÇ°¾ÈÀüÆò°¡¿ø) '17³â Á¦2ȸ ½É»ç°ü ä¿ë
°ø°í¸í: ½ÄÇ°ÀǾàÇ°¾ÈÀüÆò°¡¿ø ½É»ç°ü ä¿ë
Á¢¼ö±â°£: '17.6.22.(¸ñ) ~ 7.7.(±Ý) 18:00
Á¢¼ö¹æ¹ý: ½Ä¾àó ¿ì¼öÀÎÀçä¿ë½Ã½ºÅÛ ¿Â¶óÀÎ Á¢¼ö.......¹Ù·Î °¡±â
|
|
|
|
|
½ÅûÀÚ |
½ÂÀÎÀÏ |
Á¦Ç°¸í |
ÀÓ»ó |
´Ü°è |
¼¿ï´ëÇб³º´¿ø |
20170623 |
Àç¹ß¼º / ÀüÀ̼º µÎ°æºÎ ÆíÆò»óÇÇ¾Ï È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ ´õ¹ß·ç¸Ê°ú ´ÜÀÏÄ¡·á ¿ä¹ý°ú ´õ¹ß·ç¸Ê Æ®·¹¸á¸®¹Â¸¿ º´¿ë Ä¡·á¿ä¹ý¿¡ ´ëÇÑ Á¦2»ó ÀÓ»ó½ÃÇè |
2»ó |
MEDI4736,
Tremelimumab |
ÀϾç¾àÇ°(ÁÖ)
|
20170621 |
°Ç°ÇÑ ¿µÀ¯¾Æ ¹× ¼Ò¾Æ, û¼Ò³âÀ» ´ë»óÀ¸·Î 'ÀϾç ÀÎÇ÷翣ÀÚ ºÐÇÒ¹é½Å 4°¡'ÀÇ ¸é¿ª¿ø¼º ¹× ¾ÈÀü¼ºÀ» Æò°¡Çϱâ À§ÇÑ °ø°³(Part1), ´ÜÀϱº(Part1), ¹«ÀÛÀ§¹èÁ¤(Part2,Part3), ÀÌÁß´«°¡¸²(Part2,Part3), È°¼º´ëÁ¶(Part2,Part3) Á¦3»ó ÀÓ»ó½ÃÇè |
3»ó |
ÀϾçÇ÷ç¹é½Å4°¡ÁÖ
(ÀÎÇ÷翣ÀÚºÐÇÒ¹é½Å) |
ÄýŸÀÏÁîÆ®·£½º³»¼Å³ÎÄÚ¸®¾Æ(ÁÖ) |
20170620 |
Àç¹ß¼º ¶Ç´Â ÀüÀ̼º µÎ°æºÎ ÆíÆò»óÇǼ¼Æ÷¾Ï ½ÃÇè´ë»óÀÚÀÇ Ä¡·á¸¦ À§ÇÑ Æèºê·Ñ¸®ÁÖ¸¿°ú º´¿ëÇÑ Å»¸®¸ð°Õ ¶óÇãÆÄ·¾º¤ÀÇ Á¦ 1b/3»ó ´Ù±â°ü, ¹«ÀÛÀ§ ¹èÁ¤ ÀÓ»ó½ÃÇè |
1/3»ó |
Å»¸®¸ð°Õ ¶óÇãÆÄ·¾º¤ (Talimogene Laherparepvec) |
(ÁÖ)¾ËÅ׿ÀÁ¨ |
20170616 |
HER2 ¾ç¼º À¯¹æ¾Ï ´ë»óÀÚ Áß Ç¥ÁØÄ¡·á ½ÇÆÐÇÑ ÀüÀ̸¦ °¡Áø ÁøÇ༺ ¶Ç´Â Àç¹ß¼º ȯÀÚ¸¦ ´ë»óÀ¸·Î ALT-P7ÀÇ ¾ÈÀü¼º, ³»¾à¼º ¹× ¾àµ¿ÇÐÀ» Æò°¡Çϱâ À§ÇÑ °ø°³, ´Ü°èÀû Áõ·®, Á¦ 1»ó ÀÓ»ó½ÃÇè |
1»ó |
ALT-P7 |
|
|
|
|
|
|
|
|
FDA |
|
Drug Name and
FDA Appl. # |
Active Ingredients |
Submission
Classification |
Company |
Approval Date |
COTEMPLA XR-ODT
NDA #205489 |
METHYLPHENIDATE |
½Å¿ë·® |
NEOS THERAP INC |
06/19/2017 |
MYDAYIS
NDA #022063 |
MIXED SALTS OF A SINGLE-ENTITY AMPHETAMINE |
½Å¿ë·® |
SHIRE DEV LLC |
06/20/2017 |
RITUXAN HYCELA
BLA #761064 |
HYALURONIDASE
RITUXIMAB |
- |
GENENTECH INC |
06/22/2017 |
BEVYXXA
NDA #208383 |
BETRIXABAN |
½Å¹°Áú |
PORTOLA PHARMA INC |
06/23/2017 |
|
|
|
|
EMA |
|
Name |
Active Substance |
Therapeutic areaCompany |
Date of authorisation
/refusal |
Spinraza |
nusinersen sodium |
Muscular Atrophy, Spinal |
30/05/2017 |
Brineura |
cerliponase alfa |
Neuronal Ceroid-Lipofuscinoses |
30/05/2017 |
Elmiron |
pentosan polysulfate sodium |
Cystitis, Interstitial |
02/06/2017 |
|
|
|
|
|
|
|
Clinical.gov ¹Ì±¹ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03197506 |
Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma |
Glioblastoma
Gliosarcoma
Supratentorial Glioblastoma
|
Radiation: External Beam Radiation Therapy
Other: Laboratory Biomarker Analysis
Biological: Pembrolizumab
Radiation: Radiation Therapy
Drug: Temozolomide
Procedure: Therapeutic
Conventional Surgery
|
Mayo Clinic
National Cancer Institute (NCI) |
Phase 2 |
NCT03197025 |
Immunotherapy With
E6 T Cell Receptor (TCR)
T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions |
Human Papillomavirus
HPV-16
High Grade Squamous Intraepithelial Lesion |
Drug: Aldesleukin
Biological: E6 TCR |
Memorial Sloan Kettering Cancer Center
Y-Mabs, Inc |
Phase 1 |
NCT03196232 |
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer |
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Recurrent Esophageal Carcinoma
Recurrent Gastric Carcinoma
Stage IV Esophageal Cancer AJCC v7
Stage IV Gastric Cancer AJCC v7
Unresectable Esophageal Carcinoma |
Drug: Epacadostat
Other: Laboratory
Biomarker Analysis
Biological: Pembrolizumab
|
Pamela L. Kunz
Stanford University |
Phase 2 |
NCT03196401 |
A Study of Immunotherapy Plus Radiation Therapy to Stimulate Immunity in Solitary Bone Plasmacytoma |
Solitary Bone Plasmacytoma |
Biological: Peri-urethral and clitoral injections |
Center for Vulvovaginal Disorders |
Phase 2 |
NCT03197935 |
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer |
Triple-negative
Breast Cancer |
Drug: Atezolizumab (MPDL3280A),
an engineered anti-PDL1 antibody
Drug: Placebo
Drug: Nab-paclitaxel
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Filgrastim
Drug: Pegfilgrastim |
Hoffmann-La Roche |
Phase 3 |
|
|
|
|
Clinical.gov À¯·´ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03197467 |
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer |
Non-small Cell Lung Cancer (NSCLC) |
Drug: Pembrolizumab |
AIO-Studien-gGmbH|Merck Sharp & Dohme Corp. |
Phase 2 |
NCT03197935 |
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer |
Triple-negative Breast Cancer |
Drug: Atezolizumab (MPDL3280A),
an engineered anti-PDL1 antibody
Drug: Placebo
Drug: Nab-paclitaxel
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Filgrastim
Drug: Pegfilgrastim |
Hoffmann-La Roche |
Phase 3 |
|
|
|
|
|
Clinical.gov Áß±¹ |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03198052
|
PSCA-CAR-T or MUC1-CAR-T for Cancer With PSCA/MUC1 Expression |
Lung Cancer
Cancer
Immunotherapy
CAR-T Cell |
Genetic: PSCA or MUC1 targeting CAR-T cells |
Second Affiliated Hospital of Guangzhou Medical University |
Phase 1 |
NCT03196986 |
MIL60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer |
Non-small Cell Lung Cancer |
Drug: MIL60
Drug: Bevacizumab |
Beijing Mabworks Biotech Co., Ltd. |
Phase 3 |
NCT03196830 |
CAR-T for R/R B-NHL |
Relapsed Non Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
CAR - T CD19/CD20/CD22/CD30 |
Biological: CAR-T |
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
Phase 2 |
NCT03195491 |
A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia |
Lung Cancer
Non-Small Cell Lung Cancer |
Biological: Nivolumab |
Bristol-Myers Squibb |
Phase 3 |
NCT03195478 |
Study of Nivolumab in Combination With Ipilimumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors |
Solid Tumor |
Drug: Nivolumab
Drug: Ipilimumab |
Bristol-Myers Squibb |
Phase 1 |
|
|
|
|
Clinical.gov ÀϺ» |
NCT
Number |
Title |
Conditions |
Interventions |
Sponsor
/Collaborators |
Phases |
NCT03197935
|
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer |
Triple-negative Breast Cancer |
Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Drug: Placebo
Drug: Nab-paclitaxel
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Filgrastim
Drug: Pegfilgrastim |
Hoffmann-La Roche |
Phase 3 |
|
|
|
|
|
|
|
¹ÙÀÌ¿ÀITÇ÷§Æû '17³â ½Å±ÔÁ¦°øÁ¤º¸ ¾È³» |
¹ÙÀÌ¿ÀITÇ÷§ÆûÀÇ 2017³â ½Å±Ô Á¦°ø Á¤º¸ |
2017³âµµ¿¡´Â Áö³ ÇØ ±ÔÁ¦¡¤»ê¾÷Á¤º¸¸¦ Á¦°øÇÏ¿´´ø 12°³±¹ ¿Ü¿¡ º£Æ®³², Àεµ³×½Ã¾Æ, ÆÄÅ°½ºÅºÀÇ 3°³±¹ Á¤º¸¸¦ Ãß°¡·Î Á¦°øÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ¸¹Àº °ü½É°ú ÀÌ¿ëÀ» ºÎŹ µå¸³´Ï´Ù.
|
|
¹ÙÀÌ¿ÀITÇ÷§Æû Àü¹®ÄÁ¼³Æà ¾È³» |
2017³â¿¡´Â ÁÖ¿ä ±Ç¿ª(¹Ì±¹, À¯·´, Áß±¹)º° Àü¹® ÄÁ¼³Æà ¾÷üÀÇ ÀÎÇã°¡ Á¾ÇÕ Áö¿ø ¼ºñ½º(2017 ÷´Ü¹ÙÀÌ¿ÀÀǾàÇ° ÇØ¿ÜÁøÃâ Á¾ÇÕÁö¿ø »ç¾÷ ¡º¹ÙÀÌ¿ÀITÇ÷§Æû¡» Àü¹®ÄÁ¼³ÆÃ)¸¦ »õ·Ó°Ô ½Ç½ÃÇÒ ¿¹Á¤ÀÔ´Ï´Ù. ¸¹Àº ½Åû ¹Ù¶ø´Ï´Ù.
|
'Àü¹®ÄÁ¼³ÆÃ' À̶õ? |
¹ÙÀÌ¿ÀÀǾàÇ° ÇØ¿Ü ÀÎÇã°¡ °ü·Ã ¾÷¹«°æÇèÀÌ ÀÖ´Â Àü¹® ÄÁ¼³Æà ±â°üÀÇ
1:1(ÄÁ¼³Æñâ°ü:ÄÁ¼³Æà ÀÇ·Ú ¾÷ü) ÄÁ¼³ÆÃ
|
|
|
Èñ¸ÁÇϽô ¾÷ü²²¼´Â Çùȸ ¶Ç´Â ¹ÙÀÌ¿ÀITÇ÷§Æû ȨÆäÀÌÁöÀÇ ¡®¹ÙÀÌ¿ÀITÇ÷§Æû Àü¹®ÄÁ¼³Æà ½Åû¡¤Á¢¼ö °ø°í¡¯¸¦ È®ÀÎÇϽðí,
¡®¹ÙÀÌ¿ÀÀǾàÇ° ÇØ¿ÜÁøÃâ Àü¹®ÄÁ¼³Æà ÀÇ·Ú¼¡¯¸¦ ÀÛ¼ºÇϽþî À̸ÞÀÏ(bpis@kobia.kr) ½Åû¡¤Á¢¼öÇϽñ⠹ٶø´Ï´Ù.
µ¿ÀÏ ±â¾÷Àº ÃÖ´ë 5°Ç±îÁö ½ÉÈ, ¿¬°è ÄÁ¼³ÆÃ(´Ü°èº°) ÀÇ·Ú°¡ °¡´ÉÇÕ´Ï´Ù.
|
|
¢º ¹ÙÀÌ¿ÀITÇ÷§Æû Àü¹®ÄÁ¼³Æà Á¢¼ö°ø°í ¹Ù·Î°¡±â |
|
¢º ¹ÙÀÌ¿ÀITÇ÷§Æû ¹Ù·Î°¡±â |
|
|
|
|
|
|
|
|
|
|
|
|
|